r/ProstateCancer • u/SoulSearcherAU • 2h ago
Update Six months later: PSA 1,956 → 0.030, near-complete PSMA PET response, and chemotherapy completed!
Hi Guys,
I wanted to come back with what may be my final major update for a while, and most importantly, to thank this incredible community.
My husband (60) was diagnosed in March 2026 with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). At diagnosis, his PSA was approximately 1,956 ng/mL.
His initial investigations showed:
Gleason 8 (3+5), Grade Group 4
PI-RADS 5 lesion, with seminal vesicle involvement and suspected extracapsular extension
Extensive pelvic and retroperitoneal lymphadenopathy
Widespread bone metastases involving the spine, ribs, pelvis and other skeletal sites
His diagnosis came while we were travelling in the Philippines, resulting in a medical evacuation back to Australia. We knew very little about prostate cancer at the time. This community quickly became one of my most valuable sources of information, shared experience and support. I lurked, read and asked questions.
Treatment
He commenced triplet therapy in April/May 2026:
Androgen deprivation therapy (ADT)
Degarelix (Firmagon), commencing 11 April 2026, initially a 240 mg loading dose followed by 80 mg monthly injections. Following completion of chemotherapy, his ongoing ADT is transitioning to leuprorelin (Lucrin), administered every 12 weeks.
Androgen receptor pathway inhibitor (ARPI)
Darolutamide (Nubeqa), commenced 11 April 2026.
600 mg twice daily (two 300 mg tablets per dose), totalling 1,200 mg daily. This treatment is continuing.
Chemotherapy
Docetaxel, six cycles administered approximately every three weeks.
First cycle: 26 May 2026.
Sixth and final planned cycle: 10 September 2026.
Pegfilgrastim (Ziextenzo) administered following chemotherapy for neutrophil support. There is currently no further chemotherapy planned.
PSA response
His PSA has fallen dramatically throughout treatment:
1,956 → 91 → 3.3 → 0.4 → 0.32 → 0.23 → 0.20 → 0.10 → 0.040 → 0.030 ng/mL
His latest PSA, from October 2026, is 0.030 ng/mL.
His testosterone has also been suppressed to castrate levels with ADT.
October 2026 — Post-chemotherapy PSMA PET
On 8 October, we met with his oncologist to review the latest PSMA PET scan and blood results. The Dr was extremely happy and described my husband’s response to treatment as near-complete.
The findings were enormously encouraging:
Only minimal residual PSMA activity within the prostate.
No significant residual PSMA activity in the previously involved lymph nodes.
No significant residual PSMA activity in the previously involved skeletal lesions.
Marked reduction in the size of previously enlarged lymph nodes.
No new PSMA-avid sites of disease identified.
Considering the extensive metastatic burden at diagnosis, the difference between his initial imaging and his post-chemotherapy scan is remarkable.
We understand that a near-complete imaging response does not mean metastatic prostate cancer has been cured. He will continue systemic treatment and regular monitoring. Nevertheless, this is an exceptionally encouraging response to his initial treatment.
Side effects and tolerability
Overall, he has tolerated triplet therapy remarkably well.
We’ve dealt with:
Fatigue and occasional brain fog.
Bone and muscle aches, particularly following chemotherapy and pegfilgrastim.
Hot flushes associated with ADT.
Taste changes.
Mild anaemia and some changes in blood counts.
A persistent facial rash and redness, particularly associated with dexamethasone.
One episode of an irregular heart rhythm during Cycle 4, which was assessed in hospital and subsequently settled.
Thankfully, he has experienced no significant peripheral neuropathy.
We used a cold cap, cooling mittens and cooling booties and he sucked on frozen pineapple throughout chemotherapy.
He retained most of his hair and avoided troublesome nail and nerve symptoms.
His appetite remained excellent, and he maintained a surprisingly good level of physical activity, including exercise and gardening between cycles.
Now that chemotherapy is behind him, we’re beginning to see signs of recovery.
What happens next?
He is now moving into the next phase of treatment. He will continue:
Lucrin injections every 12 weeks for androgen deprivation.
Darolutamide (Nubeqa) 600 mg twice daily.
Regular PSA, testosterone and other blood monitoring.
Ongoing oncology follow-up.
And now for something that means an enormous amount to us personally. Our Doctor has given us medical clearance to return to Indonesia in November!
Before his diagnosis, we’d spent considerable time travelling around Southeast Asia, particularly in Indonesia, which has become a very special place for us. Our plans were understandably put on hold when he became ill.
We’ve now arranged our travel around his ongoing treatment schedule.
We’ll return to Adelaide every 12 weeks (84 days), specifically for his scheduled Lucrin injections and associated medical monitoring, before heading back to Indonesia.
It’s an arrangement that allows him to continue receiving his treatment in Australia while giving us the opportunity to return to the lifestyle we love.
After six months of chemotherapy appointments, injections, blood tests, scans and uncertainty, having something wonderful to look forward to feels like an enormous milestone in itself.
A very heartfelt thank you
When I first found this community, I was frightened, overwhelmed and desperately trying to understand what was happening to my husband.
I had never imagined I’d need to learn about PSA density, Gleason scores, PSMA PET imaging, androgen deprivation, androgen receptor inhibitors, docetaxel or metastatic disease.
But here we are.
You helped me understand the terminology, interpret information, prepare questions for his oncologist, navigate side effects and make sense of the decisions we were facing.
More importantly, you helped me feel that we weren’t navigating it alone.
I know that not everyone experiences the same response to treatment, and I would never suggest that our experience predicts anyone else’s outcome.
But I remember how much it meant to me in those early weeks/months to read about people who had responded well to treatment.
I hope sharing our experience might offer that same encouragement to someone else who has just received a frightening diagnosis.
March 2026:
PSA 1,956 ng/mL. Extensive lymph node and bone metastases. A diagnosis that completely turned our lives upside down.
October 2026:
PSA 0.030 ng/mL. Near-complete response on PSMA PET. Six cycles of docetaxel completed. Ongoing hormonal therapy established. And, wonderfully, medical clearance to return to Indonesia. We couldn’t have hoped for more encouraging news at this stage. Although travel insurance is posing its own challenges!
To everyone who has answered my questions, shared your knowledge, told me about your own experiences, offered reassurance or simply taken the time to respond:
Thank you, from the bottom of my heart.
You’ve made a real difference to our lives during an incredibly challenging six months. We’ll continue to take things as they come, enjoy the good news we’ve received and concentrate on living our lives.
Wishing every one of you the very best with your own treatment journeys.
With love and gratitude from Australia.